Autopsy report · NCT03976076

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

“Difficulty with patient recruitment due to COVID-19”

The sponsor’s own words in the registry.

Life of this trial

• Registered 10 months before it started.
• Ran for about 1 year 8 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Bio-Pharm Solutions Co., Ltd.

Sponsor type

Industry

Conditions

Refractory Infantile Spasms

Interventions

JBPOS0101

Participants

16

Sites

23

Countries

South Korea, United States

Trials that died the same way

• Iron Isomaltoside Compared With Iron Sucrosein Peritoneal Dialysis Patients
  “Difficult patient recruitment due to COVID-19 epidemic” (94% match in meaning)
• Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
  “challenges in recruitment due to covid-19” (90% match in meaning)
• Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
  “Covid 19 and difficulty with recruitment” (89% match in meaning)
• Serum Concentrations of Pregnancy-associated Proteins for Assessment of Gestational Age Before Abortion
  “COVID 19 related recruitment problems” (88% match in meaning)
• Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
  “COVID-19 challenges to recruitment” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.